The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
Unlock the market timeline & signal feed
7 signals in the last 90 days.
The order this company entered each market — oldest to newest
Medical Sales Representative
Medical Sales Representative
Sign up to see the full signal feed
How MENARINI Group's international expansion compares to its competitors
MENARINI GroupYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 MENARINI GroupYou | 4 | 0 | -83% | 7 | 14 |
Sales and Distribution Associate - 12-Month Fixed-Term Contract
View postingFlorence, Tuscany, Italy · last wk.
Italy Demand Planning Associate
View postingFlorence, Tuscany, Italy · last wk.
Global Regulatory Affairs Operations - Content Management Operational Associate
View postingIreland · 2d ago
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Menarini Group and Stemline Therapeutics will present new data on elacestrant and tagraxofusp at ASCO 2026, covering solid and hematologic cancers. Data includes ELEVATE trial results for metastatic breast cancer and updates on clinical development programs.
Menarini Group and Stemline Therapeutics announce presentation of new data on elacestrant and tagraxofusp at 2026 ASCO Annual Meeting, covering solid tumors and hematologic malignancies with multiple clinical trials.
Menarini and Stemline present Phase 1b ELEVATE study results showing elacestrant plus capivasertib combination demonstrates 88.9% disease control rate and 11.3 months median PFS in ER+/HER2- metastatic breast cancer patients.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about MENARINI Group's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
